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Assessment of health-related quality of life (HRQL) is particularly important in patients with progressive and incurable
diseases such as idiopathic pulmonary fibrosis (IPF). The St George’s Respiratory Questionnaire (SGRQ) has frequently
been used to measure HRQL in patients with IPF, but it was developed for patients with obstructive lung diseases. The
aim of this review was to examine published data on the psychometric performance of the SGRQ in patients with IPF.
A comprehensive search was conducted to identify studies reporting data on the internal consistency, construct
validity, test-retest reliability, and interpretability of the SGRQ in patients with IPF, published up to August 2013. In total,
data from 30 papers were reviewed. Internal consistency was moderate for the SGRQ symptoms score and excellent
for the SGRQ activity, impact and total scores. Validity of the SGRQ symptoms, activity, impact and total scores was
supported by moderate to strong correlations with other patient-reported outcome measures and with a measure of
exercise capacity. Most correlations were moderately strong between SGRQ activity or total scores and forced or static
vital capacity, the most commonly used marker of IPF severity. There was evidence that changes in SGRQ domain and
total scores could detect within-subject improvement in health status, and differentiate groups of patients whose
health status had improved, declined or remained unchanged. Although the SGRQ was not developed specifically for
use with patients with IPF, on balance, its psychometric properties are adequate and suggest that it may be a useful
measure of HRQL in this patient population. However, several questions remain unaddressed, and further research is
needed to confirm the SGRQ’s utility in IPF.
Keywords: Idiopathic pulmonary fibrosis, Patient-reported outcomes, PROs, St George’s Respiratory Questionnaire,
SGRQ, Health-related quality of life, HRQL, Psychometrics, Validity, ReliabilityIntroduction
Idiopathic pulmonary fibrosis (IPF) is a specific form of
fibrosing interstitial pneumonia characterized by pro-
gressive worsening of dyspnea and lung function [1]. In
the United States, the annual incidence of IPF has been
estimated as 6.8–8.8 cases per 100,000 using narrow
case definitions (requiring a definite pattern of Usual
Interstitial Pneumonia [UIP] on high-resolution com-
puted tomography [HRCT]), and as 16.3–17.4 cases per
100,000 using broad case definitions (including patients
with a possible UIP-pattern on HRCT) [2]. Although IPF* Correspondence: swigrisJ@NJHealth.org
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unless otherwise stated.has a poor prognosis, with a median survival time from
diagnosis of 2 to 3 years, the clinical course of IPF varies
considerably [1,3]. Symptoms experienced by patients
with IPF include non-productive cough, fatigue and
chronic dyspnea, with the latter being the most promin-
ent and disabling [4]. The morbidity associated with IPF
has a broad and profound impact on patients’ health-
related quality of life (HRQL) [4,5].
As IPF is a progressive disease with no cure, HRQL
and other patient-centered outcomes are important end-
points to evaluate in research and clinical practice [6].
Although no disease-specific measure of HRQL has been
established as suitable for longitudinal research in pa-
tients with IPF, several HRQL instruments (and others,
including symptom and generic quality of life question-
naires) have been used [7,8]. Which patient-centeredLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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a particular study depends on a number of factors, in-
cluding the design of the study, the intervention being
assessed, the hypotheses being tested, and the character-
istics of the comparator group (general population,
patients with IPF of different severity, patients with an-
other disease, etc.). In any situation, whether a generic
HRQL instrument might perform as well or better than
a disease-specific HRQL instrument is uncertain.
In this review, we focused on the St George’s Respiratory
Questionnaire (SGRQ). Although originally developed for
use in patients with chronic obstructive pulmonary disease
(COPD) and asthma [8], it has frequently been used to
evaluate HRQL in patients with IPF. The SGRQ is a 50-
item questionnaire split into three domains: symptoms
(assessing the frequency and severity of respiratory symp-
toms), activity (assessing the effects of breathlessness on
mobility and physical activity), and impact (assessing the
psychosocial impact of the disease) [9]. Scores are
weighted such that every domain score and the total score
range from 0 to 100, with higher scores indicating a
poorer HRQL.
The aim of this review was to assess the appropriate-
ness of the SGRQ for measuring HRQL in patients with
IPF by examining the evidence relating to the psycho-
metric performance of the SGRQ in this population. A
revised version of the SGRQ, the SGRQ-I, has been de-
veloped for use in patients with IPF [10]; however, stud-
ies assessing this tool are limited, and SGRQ-I data are
not covered in this manuscript.Figure 1 Selection of articles to be included in the review.Methods
Search strategy and data extraction
A comprehensive literature review was conducted to
identify articles that evaluated the psychometric proper-
ties of the SGRQ in patients with IPF. Following a
PubMed search (see Additional file 1), articles were ex-
cluded if they were not published between 1 January
1991 (date of first publication of the SGRQ) and 31
August 2013, were not published in English, did not re-
port data on the psychometric properties of the SGRQ
in patients with IPF or duplicated clinical trial data re-
ported in another article (Figure 1). Data extracted from
the studies included study characteristics (country, dur-
ation, design, sample size), participant characteristics
(age, gender, time since diagnosis, forced vital capacity
[FVC]% predicted, diffusing capacity for carbon monox-
ide [DLCO]% predicted) and results of the psychometric
tests.
Articles were selected that assessed any of the follow-
ing psychometric properties of the SGRQ: internal
consistency, convergent validity, known groups validity,
test-retest reliability (reproducibility), responsiveness,
minimal important difference (MID), and floor and ceil-
ing effects [11]. Internal consistency refers to the degree
to which the individual items within an instrument cor-
relate with each other (i.e., tap the same underlying con-
struct). This is determined using Cronbach’s coefficient
alpha, with ≥0.70 considered to indicate acceptable in-
ternal consistency for a multi-dimensional instrument.
Convergent validity describes the degree to which two
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correlate. Known groups validity refers to the extent to
which scores on an instrument distinguish groups that
differ on a key variable, usually clinical in nature. For the
described validity measures, correlations were regarded
as weak if ≤0.30, moderate if 0.30–0.60, and strong
if >0.60 [12]. Test-retest reliability assesses the ability of
an instrument to produce consistent scores over repeated
measurements in patients who are clinically stable. Re-
sponsiveness assesses the ability of an instrument to detect
change in individuals who are hypothesized to have chan-
ged on the underlying construct (HRQL) and who are
known to have experienced change in clinical status. MID
estimates identify the smallest difference in the score on
an instrument that patients perceive as important. Floor
and ceiling effects are limitations that occur when an indi-
vidual scores at the extremes of an instrument; if a pa-
tient’s score is the lowest or highest possible value, the
instrument is unable to detect a reduction or increase,
respectively.
Results
A total of 30 papers were included in the review (Figure 1;
Table 1).
Internal consistency
Data from a clinical trial of bosentan have been used to
determine the internal consistency of the SGRQ in pa-
tients with IPF. Cronbach’s alpha was 0.66 for the symp-
toms score and ≥0.84 for each of the SGRQ activity,
impact and total scores [10,34].
Convergent validity
Convergent validity was evaluated by extracting cross-
sectional and longitudinal correlations between SGRQ
scores and other patient-reported outcome measures
(Table 2), an assessment of exercise capacity (Table 3),
pulmonary function tests (PFTs) or partial pressure of
arterial oxygen (Table 4), and assessments of fibrotic ab-
normalities on HRCT (Table 5).
Patient-reported outcome measures
In nine studies, investigators provided information on the
correlation between SGRQ scores and other patient-
reported outcome measures (BDI [Baseline Dyspnea
Index], D-12 [Dyspnea-12], K-BILD [King’s Brief Intersti-
tial Lung Disease questionnaire], UCSD-SOBQ [University
of California San Diego Shortness of Breath Question-
naire], CQLQ [Cough Quality of Life Questionnaire], a
single-item dyspnea assessment, SF-36 Physical Compo-
nent Summary score [SF-36 PCS] and the Borg Dyspnea
Index) (Table 2). Moderate to strong correlations were ob-
served between the SGRQ total score and the total scores
on these instruments (Table 2). In general, moderate tostrong correlations were observed between SGRQ domain
scores and the total scores on these instruments. Likewise,
moderate to strong correlations were observed between
SGRQ domain or total scores and the total, physical com-
plaints, extreme physical complaints, and functional abil-
ity sub-scale scores of the CQLQ (r = 0.34 to 0.81) [21],
the total and sub-scale scores of the K-BILD (r = -0.59
to -0.89) [27], the SF-36 PCS, a composite score measur-
ing overall physical health (r = -0.52 to -0.74) [10] and the
Borg Dyspnea index (r = 0.35 to 0.56) [10,15]. For most
measures and their sub-scales, correlations were weakest
with the SGRQ symptoms score (when compared with
other SGRQ domains or the total score).
In two studies, investigators evaluated correlations be-
tween SGRQ change scores and change scores from other
patient-reported outcome measures (Table 2). In one
study, correlations were moderately strong between
change scores for the SGRQ activity, impact and total
scores and change scores from the single-item dyspnea as-
sessment (r = 0.59, 0.56 and 0.45, respectively) [28]. In the
other study, investigators found that the correlation be-
tween the BDI change score and SGRQ total change score
was -0.29 and not significant [25]. However, the BDI was
designed to measure dyspnea severity at a single point in
time and not to measure change in dyspnea severity [42].
Measures of exercise capacity
Correlation coefficients between SGRQ scores and a
measure of exercise capacity are presented in Table 3. Dis-
tance covered during the 6-minute walk test (6MWD) is
frequently used as a measure of exercise capacity in pa-
tients with IPF, and change in 6MWD has been shown to
be a predictor of mortality in these patients [16]. In five
cross-sectional studies in patients with IPF, investigators
examined the relationship between the SGRQ total score
and 6MWD. The strength of these correlations was mod-
erate to strong in three (-0.45 to -0.72) [15,28,40] and
weak in two (-0.26 and -0.28) [10,16] studies. In four
cross-sectional studies, investigators examined the rela-
tionship between the SGRQ domain scores and the
6MWD [10,28,39,40]; the strength of these correlations
was moderate to strong for the activity score in all four
studies (r = -0.32 to -0.72), moderate to strong for the im-
pact score (r = -0.41 to -0.63) and moderate for the symp-
toms score (r = -0.32 to -0.41) in three studies. In three
studies, investigators examined the relationship between
change scores for the SGRQ total and change in 6MWD;
[16,25,28]correlation coefficients ranged from -0.23 to -0.43.
Pulmonary function tests and arterial blood gas analysis
Table 4 presents correlations between SGRQ scores and
either PFTs or arterial blood gas analysis in patients with
IPF. All correlations between the SGRQ total score
and these variables were moderate to strong (r = -0.30
Table 1 Studies included in this review






Baseline SGRQ score2 Baseline spirometric values2






Greece 50 50 T = 49.4 (24.3)
C = 42.7 (16.8)
– T = 71.8 (15.0)











n/a US 50 33 – Total = 38.9 [28.7–55.2]
Symptoms domain = 50.5 [31.5–69.8],
Activity domain = 54.4 [39.9–72.9],
Impact domain = 28.4 [18.8–45.1]
65.0 (49.0–81.0) 49.0 (36.5–59.8)




Multi-national 822 822 – Total = 41.8 (18) 72.5 (12.7) 47.4 (9.2)
Han et al.,
2013 [17]
RCT Sildenafil US 119 119 20.4 – 56.9 26.0
Horton et al.,
2012 [18]
RCT Thalidomide US 23 23 20.5 (3–59) Total = 57.4 (18.8)
Symptoms domain = 67.7 (19.7),
Activity domain = 64.3 (22.7),
Impact domain = 48.1 (20.7)
70.4 (13.7) 57.4 (14.4)
King, Jr. et al.,
2008 [19]
RCT Bosentan Multi-national 158 158 T = 12.2 (12.2)
C = 12.1 (12.0)
T-Total = 45.7 (18.1), C-Total = 45.2 (19) T = 65.9 (10.5),
C = 69.5 (12.6)
T = 42.3 (9.5),
C = 41.4 (9.5)




Multi-national 826 826 – T-Total = 41.6 (17.9), C-Total = 42.4 (18.2) T = 72.2 (12.3),
C = 73.1 (13.4)
T = 47.4 (9.2),
C = 47.3 (9.3)
Lechtzin et al.,
2013 [21]
RCT Thalidomide US 24 24 – Total = 57.4 (18.8),
Symptoms domain = 67.7 (19.7),
Activity domain = 64.3 (22.7),
Impact domain = 48.1 (20.7)
70.4 (13.7) 57.4 (14.4)
Mishra et al.,
2011 [22]










n/a Japan 41 41 – Total = 35.7 (20.6) [range 1.6–77.6],
Symptoms domain = 40.1 (24.6)
[range 4.4–85.6], Activity domain = 44.5































Japan 28 28 – T-Total = 50.2 (16.3),
T-Symptoms domain = 56.4 (22.3),
T-Activity domain = 64.7 (17.1),
T-Impact domain = 39.7 (17.6),
C-Total = 37.8 (22.7),
C-Symptoms domain = 38.0 (25.8),
C-Activity domain = 50.4 (26.2),
C-Impact domain = 29.9 (23.7)
T = 66.1 (13.2),
C = 68.7 (19.5)
T = 59.4 (16.7),
C = 48.6 (16.7)
Noth et al.,
2012 [26]
RCT Warfarin US 145 145 T = 21.6, C = 25.2 T-Total = 46.2 (18.0), C-Total = 50.1 (17.2) T = 58.9 (16.2),
C = 58.7 (16.1)
T = 33.8 (12.4),










n/a China 68 68 14.0 (14.0) Total = 54 (15),
Symptoms domain = 65 (16),
Activity domain = 56 (15),
Impact domain = 49 (19)





Multi-national 330 330 – – T = 63.9 (10.7),




RCT Etanercept Multi-national 88 88 T = 14.7 (19.8),
C = 12.3 (13.6)
T-Total = 40.8 (18.1), C-Total = 42.9 (19.4) T = 64.7 (14.1),
C = 63.0 (12.7)
T = 36.3 (12.6),
C = 36.9 (10.8)
Raghu et al.,
2013 [31]
RCT Ambrisentan Multi-national 492 492 T = 13.2, C = 10.8 T-Total = 44.5 (21.6), C-Total = 40.5 (21.1) T = 68.7 (13.1),
C = 69.9 (13.8)
T = 42.0 (13.8),










Multi-national 428 428 T, 50 mg qd = 16.8
(15.6), T, 50 mg
bid = 13.2 (14.4),
T, 100 mg bid = 14.4
(14.4), T, 150 mg
bid = 12 (14.4),
C = 16.8 (18)
T, 50 mg qd-Total = 43.7 (17.5),
T, 50 mg bid-Total = 42.5 (17.0),
T, 100 mg bid-Total = 43.7 (16.6),
T, 150 mg bid-Total = 40.1 (18.3),
C-Total = 41.2 (17.9)
T, 50 mg qd = 80.4
(17.8), T, 50 mg bid = 79.8
(15.8), T, 100 mg bid = 85.5
(19.2), T, 150 mg bid = 79.1






Bosentan Multi-national 158 158 – Total = 44.8 (19.5),
Symptoms domain = 50.1 (21.9),
Activity domain = 60.6 (22.8),
Impact domain = 33.7 (20.6)










n/a Greece 25 25 31.2 Total = 37.7 (18.9),
Symptoms domain = 55.9 (25.3),
Activity domain = 36.2 (21.4),






Greece 14 14 – – – –





























Total = 63.4 (3.7–96.3),
Symptoms domain = 59.8 (0–97.2),
Activity domain = 81.6 (6.0–99.5),










n/a Multi-national 101 67 – Total = 53 (24),
Symptoms domain = 61 (23),
Activity domain = 65 (30),
Impact domain = 41 (24)





n/a Brazil 22 22 – Total = 48.4 (17.9),
Symptoms domain = 46.4 (20.3),
Activity domain = 62.4 (19),
Impact domain = 43.6 (20.9)
70.4 (19.4) 41.5 (16.2)
Zisman et al.,
2010 [41]
RCT Sildenafil US 180 180 T = 24.4, C = 22.4 T-Total = 54.55 (16.46), C-Total = 51.72 (15.86) T = 54.9 (14.00),
C = 58.7 (14.12)
–
1Sample size reported represents the population in which efficacy was assessed. RCT = randomized controlled trial; T = treatment group; C = comparator group; qd = once daily; bid = twice daily. 2Mean (SD) or









































Chang et al., 1999 [15] Borg Dyspnea Index 0.56†
Lechtzin et al., 2013 [21] CQLQ Total 0.72* 0.72‡ 0.81‡ 0.79‡
Physical complaints 0.50* 0.72‡ 0.71‡ 0.77‡
Psychological issues 0.29 0.40 0.62† 0.54*
Functional ability 0.53* 0.54* 0.66† 0.66†
Emotional well-being 0.19 0.42 0.57† 0.50*
Extreme physical complaints 0.38 0.34 0.63† 0.54*
Personal safety fears 0.05 0.23 0.45* 0.34
Nishiyama et al., 2005 [24] BDI −0.55‡ −0.77§ −0.53‡ −0.69§
Patel et al., 2012 [27] K-BILD Total −0.67† −0.79† −0.87† −0.89†
Psychological −0.60† −0.67† −0.80† −0.79†
Breathlessness −0.59† −0.84† −0.80† −0.86†
Chest −0.65† −0.64† −0.79† −0.78†
Peng et al., 2008 [28] Dyspnea score NS 0.58§ 0.30† 0.38‡
Swigris et al., 2012 [35] UCSD-SOBQ 0.80§
Yorke et al., 20101 [10] BDI −0.39§ −0.72§ −0.61§ −0.68§
SF-36 PCS −0.52§ −0.74§ −0.63§ −0.71§
Borg Dyspnea Index 0.35§ 0.45§ 0.40§ 0.45§
Yorke et al., 2011 [39] D-12 0.57‡ 0.78‡ 0.75‡ 0.79‡
Zimmermann et al., 2007 [40] BDI −0.62* −0.75* −0.63* −0.72*
Longitudinal studies
Nishiyama et al., 2008 [25] Δ BDI −0.29
Peng et al., 2008 [28] Δ Dyspnea score NS 0.59† 0.56† 0.45†
BDI = Baseline Dyspnea Index; CQLQ = Cough Quality of Life Questionnaire; D-12 = Dyspnea-12; K-BILD = King’s Brief Interstitial Lung Disease questionnaire;
SF-36 PCS = SF-36 Physical Component Summary; UCSD-SOBQ = University of California San Diego Shortness of Breath Questionnaire; Δ = change.
*p < 0.05; †p < 0.01; ‡p < 0.001; §p < 0.0001; NS = non-significant. 1Data reported refer to the original version of the SGRQ, not the SGRQ-I.
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http://www.hqlo.com/content/12/1/124to -0.66, and p < 0.05 for all but one). There were
moderate to strong correlations between the SGRQ activ-
ity score and the majority of pertinent PFT results (e.g.,
FVC or DLCO) or arterial blood gas analysis in all stud-
ies, while correlations between the SGRQ symptoms or
impact domain scores and these variables were gener-
ally weak to moderate. Results for FVC, the lung func-
tion parameter regarded as the most statistically useful
physiological indicator of IPF severity, and the one
most frequently used as a primary endpoint in contem-
porary clinical trials, were weakly to moderately corre-
lated with SGRQ total and domain scores (r = -0.34
to -0.45 for the SGRQ total and -0.13 to -0.31 for the
SGRQ domains).
HRCT
In one study of patients with IPF, investigators assessed
correlations between SGRQ scores and the extent offibrotic abnormalities on HRCT (degree of ground-glass
opacity [CT-alv], interstitial opacity [CT-fib], and both
[total score]) (Table 5). Correlations were moderately
strong between the SGRQ symptoms, impact and total
scores and CT-alv or total scores (r = 0.34 to 0.42) and
moderately strong between the SGRQ activity score and
both the CT-fib and total scores (r = 0.37 to 0.39) [28].
Known groups validity
Although there are no well-established categories of dis-
ease severity in IPF, it may be hypothesized that patients
receiving supplemental oxygen represent patients with
more severe disease. In two studies, investigators found
that SGRQ total scores were worse in patients using
supplemental oxygen versus those not using supplemen-
tal oxygen [15,38]. In one study by Chang and col-
leagues, the magnitude of difference between patients
using versus not using oxygen was 4.7 (p < 0.05) [15].














Chang et al., 1999 [15] 6MWD −0.66†
du Bois et al., 2011 [16] 6MWD −0.26‡
Peng et al., 2008 [28] 6MWD −0.32† −0.43‡ −0.41‡ −0.45‡
Yorke et al., 20101 [10] 6MWD −0.14 −0.32§ −0.24† −0.28†
Yorke et al., 2011 [39] 6MWD −0.32† −0.54† −0.47†
Zimmermann et al., 2007 [40] 6MWD −0.41 −0.72* −0.63* −0.72*
Longitudinal studies
du Bois et al., 2011 [16] Δ 6MWD −0.231‡
Nishiyama et al., 2008 [25] Δ 6MWD −0.43*
Peng et al., 2008 [28] Δ 6MWD NS −0.43 −0.46 −0.41†
6MWD = Distance covered in 6-minute walk test; Δ = change.
*p < 0.05; †p < 0.01; ‡p < 0.001; §p < 0.0001; NS = non-significant. 1Data reported refer to the original version of the SGRQ, not the SGRQ-I.
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No studies were found that reported data on the test-
retest reliability of the SGRQ in patients with stable IPF.
Minimal important difference
A triangulation approach has been used to determine an
MID estimate for SGRQ scores in patients with IPF [34].
Using both distribution- and anchor-based approaches
(using FVC, DLCO and the TDI as anchors), the MID for
the SGRQ symptoms, activity, impact and total scores was
8, 5, 7 and 7 respectively.
Responsiveness
The responsiveness of the SGRQ domain and total scores
has been assessed in one study [34]. Using data from a ran-
domized placebo-controlled trial of bosentan, investigators
assessed the ability of the SGRQ to discriminate among
IPF patients who had experienced an improvement, de-
cline, or no change in disease status over 6 months, as de-
fined by three clinical anchors (change in FVC, DLCO,
transition dyspnea index [TDI]). With the exception of the
SGRQ symptoms score when DLCO was the anchor,
changes in SGRQ domain and total scores differed signifi-
cantly between patients who had declined, remained stable,
or improved. [34]. Change scores from the SGRQ total and
its domains were reported for the DLCO and TDI response
categories and ranged from +3 to +13, +1 to -5, and 0
to -12 for patients that declined, remained stable, or im-
proved, respectively. The impact domain discriminated best
between all categories of change for all three anchors [34].
SGRQ as an endpoint
In sixteen trials, investigators used the SGRQ domain
and/or total scores as outcome variables. In four trials,investigators evaluated the within-subject change in
SGRQ total score from baseline to end of treatment
[22,23,32,37] (Table 6). In all four, improvements were ob-
served in exercise endurance or FVC; among these, in
three there was a significant decrease in SGRQ total score
from baseline to end of treatment (8–24 weeks).
In the remaining 12 trials, investigators assessed
whether the SGRQ domain and/or total scores differed
between active and placebo groups (Table 7). In four of
these [13,17,18,25], statistically significant between-group
differences for the primary endpoint coincided with statis-
tically significant between-group differences in at least one
SGRQ total or domain score (range of between-groups
difference in SGRQ total score: -6.1 to -13.4). Six studies
[17,20,26,29-31] reported a lack of statistically significant
treatment effect in the primary endpoint or SGRQ scores
(range of between-groups difference in SGRQ total score
reported in three studies: -0.5 to -3.0; scores were not re-
ported in three studies). In three studies [19,33,41], the
primary endpoint was not met, but the SGRQ total or do-
main scores were significantly different between treatment
groups (range of between-groups difference in SGRQ total
score: -3.3 to -6.1).
Four studies [20,31,33,41] reported changes from base-
line in SGRQ total score in the placebo group. Adjusting
for different trial durations, the SGRQ total score in the
placebo arms of these trials deteriorated (increased) by a
median of +4.9 (range: 3.2 to 10.6) per 52 weeks.
Floor and ceiling effects
No studies were found in which investigators reported data
on floor and ceiling effects for the SGRQ in patients with
IPF. However, in most studies, the minimum and maximum
achievable SGRQ total scores (0 and 100, respectively) were
Table 4 Correlation coefficients between SGRQ scores, pulmonary function tests and arterial blood gas analysis

























TLC −0.48† −0.38* −0.21 −0.36*
TLCO −0.32* −0.45
† −0.27 −0.39*
VC −0.35* −0.36* −0.15 −0.30
Peng et al., 2008 [28] DLCO% predicted −0.46
§ −0.46§ −0.34† −0.44‡




TLC% predicted −0.50§ −0.61§ −0.52§ −0.62§
VC% predicted NS −0.59§ −0.35† −0.47§
Tzanakis et al., 2005 [36] FEV1% predicted −0.50
†
PaO2 (at rest) −0.51
†
PaO2 (at exertion) −0.60
†
TLC% predicted −0.55†
Yorke et al., 20101 [10] FVC% predicted −0.27† −0.31§ −0.30§ −0.34§
TLCO% predicted −0.23
† −0.34§ −0.38§ −0.38§
Yorke et al., 2011 [39] DLCO% −0.16 −0.37
† −0.28*
FVC% −0.13 −0.16 −0.24*
Zimmermann et al., 2007 [40] DLCO% predicted −0.41 −0.32 −0.39 −0.47*
FEV1% predicted −0.08 −0.57* −0.52* −0.57*
TLC% predicted −0.37 −0.65* −0.58* −0.66*
VC% predicted −0.14 −0.54* −0.61* −0.56*
DLCO = diffusion capacity of the lung for carbon monoxide; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; PaO2 = partial pressure of
oxygen dissolved in arterial blood; TLC = total lung capacity, TLCO = transfer factor of the lung for carbon monoxide; VC = vital capacity.
*p < 0.05; †p < 0.01; ‡p < 0.001; §p < 0.0001; NS = non-significant. 1Data reported refer to the original version of the SGRQ, not the SGRQ-I.
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http://www.hqlo.com/content/12/1/124outside an interval spanning twice the standard deviation
around the reported means (Table 1). For the two studies
in which investigators reported ranges for baseline SGRQ
total scores, ranges did not include minimum or max-
imum possible values [24,38], thus confirming the absence
of floor or ceiling effects in these studies.Table 5 Correlation coefficients between SGRQ scores and ex
Study HRCT measure Correlation with
SGRQ symptoms
domain score
Peng et al., 2008 [28] CT-alv 0.41†
CT-fib NS
CT-tot 0.36*
CT-alv = ground glass opacity; CT-fib = interstitial opacity; CT-tot = total.
*p < 0.01; †p < 0.001; NS = non-significant.Conclusions
Measurement standards and psychometric criteria have
been proposed to assist with choosing an appropriate in-
strument to evaluate HRQL in patients with IPF [6,43].
As with any patient-reported outcome measure used in


















Sample size SGRQ total score1 Effect
size
p-value2
Total IPF Baseline Post-treatment
Mishra et al., 2011 [22] Oral doxycycline 24 weeks 6 6 50.90 (8.38) 18.40 (6.39) 3.88 <0.001
Naji et al., 2006 [23] Pulmonary rehabilitation 8 weeks 26 19 48.3 [21.5, 82] 39.5 [17.4, 69.4] 0.41 <0.10
Rammaert et al., 2009 [32] Pulmonary rehabilitation 8 weeks 13 13 – – – NS
Tzouvelekis et al., 2013 [37] Endobronchial infusion of
adipose-derived stromal cells
6 months 14 14 35.1 (6.8) 27.8 (5.6) 1.07 <0.05
1Mean (SD) or median [range] are reported based on availability.
2p-value for test of statistical significance between SGRQ score at baseline and post-treatment.
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tudinal validity, and minimal floor and ceiling effects in
the target patient population.
The constellation of findings from studies identified in
our search revealed that in patients with IPF, the internal
consistency of the SGRQ activity and impact domains
and the SGRQ total score was excellent, and the internal
consistency of the symptoms domain was moderate, and
in most studies, fell below the acceptable threshold of
0.7. The lower internal consistency of the symptoms do-
main is likely because it asks about a range of respiratory
symptoms (cough, sputum, shortness of breath, wheez-
ing and attacks of chest trouble), the majority of which
apply to few patients with IPF whose major symptoms
are shortness of breath and cough. In response data, off-
target items create a weaker level of inter-relatedness
among items in this domain, and thus lower internal
consistency. This also contributes to the lower conver-
gent validity of this domain, as the off-target items
weaken the associations between its scores and clinical
measures of IPF severity (e.g., patients may endorse
wheezing or attacks of chest trouble, but these symp-
toms are unlikely related to a person’s FVC). These off-
target (for IPF) items in the symptoms domain detract
from the SGRQ’s face validity and would likely have
been removed or modified in a tool specifically designed
for use with patients with IPF. Overall, the symptoms
domain may be well-suited for patients with COPD, but
is not tailored to precisely assess symptoms in patients
with IPF. The non-informative noise in the symptoms
domain might also contribute to a less than optimal per-
formance of the SGRQ total score. Overall, however,
despite its weak face validity in IPF, the symptoms do-
main performs reasonably well in this population, and
its potential to detract from the performance of the
SGRQ total score is tempered because it contributes
least to the SGRQ total score.
Convergent validity analyses seek to determine whether
two measures, hypothesized to measure the same con-
struct, do in fact correlate, and moderate, statistically
significant correlations in the expected direction sup-
port convergent validity. Very strong or ‘perfect’ cor-
relations, suggest redundancy in measurement, somoderate correlations between a patient-reported out-
come measure and another clinical variable support con-
vergent validity of the patient-reported outcome measure
while confirming that it contributes unique information
not captured by the other clinical variable [5]. The SGRQ
has been used as a secondary endpoint in several clinical
trials conducted in patients with IPF. Among the select
few in which the intervention outperformed placebo,
SGRQ results were as one would anticipate, i.e., SGRQ
scores improved in the group that benefited from the
intervention. Although not a formal assessment of re-
sponsiveness, consistency between the changes in SGRQ
scores and the changes in other endpoints supports
responsiveness.
In sum, the limitations of the SGRQ in IPF should be
noted, as it was not originally developed for use in pa-
tients with IPF. In particular, this applies to possible
over-interpretation of results of individual domains.
However, the cross-sectional correlations between SGRQ
domain and total scores and other measures of patient-
reported health status, exercise capacity or lung func-
tion, along with the ability of the SGRQ to distinguish
patients who experience a change in clinical status or re-
main stable over time, support the SGRQ as a useful
patient-reported outcome measure in IPF.
Limitations to our research include the following: we
could only identify one study in which MID estimates
for the SGRQ scores in IPF were determined [44]. This
study used a triangulation approach and concluded an
MID that was higher than that reported for COPD [45],
but more research with additional datasets is needed to
evaluate these estimates. In the meantime, the use of re-
sponder rates of patients experiencing a minimum
change from baseline in SGRQ scores – or perhaps
more informative, cumulative distribution plots – may
be a useful assessment, as research suggests that it may
be less dependent on the exact cutoff, i.e. the precise
value of the MID [46].
No articles were identified that evaluated the test-
retest reliability of the SGRQ in patients with stable IPF.
Likewise, we could not locate a study in which floor and
ceiling effects of SGRQ scores were reported, although
an analysis of the reported baseline mean SGRQ total























12 months 50 Interferon gamma b −13.2 [21.4,5.0] −4.8 [-12.7, 3.0] −1.9 [-9.2, 5.4] −4.7 [-11.4, 2.0]
Colchicine 7.5 [-4.5, 19.5] 4.7 [-12.1, 22.0] 4.1 [-6.4, 14.6] 4.8 [-5.9, 15.5]
p-value2 0.01 NS NS NS
Han et al.,
2013 [17]
12 weeks 22 Sildenafil (with RVSD) – – – –
Placebo (with RVSD) – – – –
Difference1 −28.0 [-41.7, -14.4] −5.6 [-16.1, 5.0] −14.0 [-25.6, -2.4] −13.4 [-22.7, -4.2]
p-value2 <0.0001 NS 0.02 0.005
97 Sildenafil (without RVSD) – – – –
Placebo, (without RVSD) – – – –
Difference1 −3.8 [-10.7, 3.0] −4.1 [-9.2, 1.1] −1.8 [-7.5, 3.9] −3.0 [-7.6, 1.7]
p-value2 NS NS NS NS
Horton et al.,
2012 [18]
12 weeks 23 Thalidomide – – – –
Placebo – – – –
Difference1 −12.1 [22.2,2.0] −3.3 [-9.8, 3.2] −13.1 [-19.7, -6.6] −11.7 [-18.6, -4.8]
p-value2 0.018 NS <0.001 0.001
King, Jr. et al.,
2008 [19]
6 months4 158 Bosentan – – – –
Placebo – – – –
Difference1 – – – −3.3 (2.6)
p-value2 – – – 0.034
King, Jr. et al.,
2009 [20]
77 weeks 826 Interferon gamma b – – – 5.7 (13.5)
Placebo – – – 6.2 (14.3)
p-value2 – – – NS
Nishiyama et al.,
2008 [25]
10 weeks 28 Pulmonary rehabilitation – – – –
No pulmonary rehabilitation – – – –
Difference1 −5.7 [-18.7, 7.2] −5.8 [-14.7, 3.1] −6.2 [-12.8, 0.3] −6.1 [-11.7, 0.5]
p-value2 NS NS NS <.05
Noth et al.,
2012 [26]
28 weeks 145 Warfarin – – – –
Placebo – – – –
p-value2 – – – NS
Raghu et al.,
2004 [29]
48 weeks 330 Interferon gamma 1b – – – –
Placebo – – – –
p-value2 – – – NS
Raghu et al.,
2008 [30]
48 weeks 88 Etanercept – – – –
Placebo – – – –
Difference1 – – – –
p-value2 NS NS NS NS
Raghu et al.,
2013 [31]
48 weeks 492 Ambrisentan – – – 4.7
Placebo – – – 3.0
p-value2 – – – NS
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Table 7 Changes in SGRQ scores in randomized controlled trials (Continued)
Richeldi et al.,
2011 [33]
12 months 431 Nintedanib 50 mg qd 3.39 (2.51) 7.39 (1.96) 3.71 (2.04) 4.67 (1.78)
Nintedanib 50 mg bid 2.11 (2.34) 3.54 (1.82) 1.73 (1.90) 2.18 (1.65)
Nintedanib 100 mg bid 2.33 (2.35) 3.00 (1.83) 0.79 (1.91) 1.48 (1.66)
Nintedanib 150 mg bid −3.14 (2.40) 0.32 (1.89) −0.14 (1.97) −0.66 (1.71)
Placebo 6.45 (2.45) 7.48 (1.91) 4.21 (1.99) 5.46 (1.73)
p-value3 <0.005 <0.005 – <0.01
Zisman et al.,
2010 [41]
12 weeks 180 Sildenafil −3.58 [-7.02, -0.13] −1.15 [-3.68, 1.38] −0.88 [-3.78, 2.02] −1.64 [-3.91, 0.64]
Placebo 2.15 [-1.30, 5.61] 2.49 [0.00, 4.99] 2.82 [-0.03, 5.67] 2.45 [0.17, 4.72]
Difference1 −5.73 [-10.61, -0.85] −3.64 [-7.20, -0.09] −3.70 [-7.76, 0.37] −4.08 [-7.30, -0.86]
p-value2 0.02 .04 NS .01
RVSD = right ventricular systolic dysfunction.
1Difference in change from baseline between treatment groups, mean [95% CI].
2Test of statistical significance for the difference in mean change from baseline between groups.
3Test of statistical significance for the difference in mean change from baseline between the nintedanib 150 mg bid and placebo groups.
4Treatment continued for ≥12 months (data not available).
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was no evidence for either. Furthermore, we did not as-
sess the content validity of the SGRQ in patients with
IPF, nor did we include analyses of articles published in
languages other than English. Content validity and cul-
tural adaption are important factors to consider for any
patient-reported outcome measure, but these topics
were beyond the scope of this evaluation of the SGRQ’s
psychometric properties. Therefore, it is evident that
more research on the SGRQ is needed in this patient
population.
The utility of a patient-reported outcome measure
may be assessed only after a wealth of data becomes
available. The assessment involves examining how the
measure performs in the target population under several
circumstances. The cache of available data has greatly
advanced our understanding of HRQL in general, and
the performance of the SGRQ in patients with IPF. For
example, whilst the mean baseline SGRQ total score re-
ported in IPF (around 45; interquartile range: 42–50) is
similar to that reported in COPD trials [47,48], an ana-
lysis of the reported changes from baseline in the SGRQ
total score in the placebo arms suggests that untreated
patients with IPF deteriorate by +4.9 points over a
period of 52 weeks. This contrasts with the experience
in COPD, where patients on placebo show an improve-
ment of 2–3 points per year [46], and reflects the progres-
sive decline in health status seen in patients with IPF.
Finally, a major factor in this assessment revolves
around how confidently response data from the measure
can be used to make inferences about patients in the tar-
get population. For example, what can be said about a
patient with IPF whose SGRQ score is 50? How does
day-to-day functioning, or how a patient feels, change
for an IPF patient whose SGRQ score increases by 10
over 6 months? Being able to answer these, and similar,questions confidently and accurately will further and
more strongly support the validity of the SGRQ as an in-
strument capable of assessing domains of HRQL in this
population. Until then, the balance of the data suggests
that the SGRQ may be a suitable secondary endpoint for
measuring HRQL in therapeutic trials of IPF.Additional file
Additional file 1: PubMed search strategy.
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